MLEC revenueFY2025$333.61M
- FY YoY
- -28.5%
MLEC revenue was $333.61M for fiscal 2025 (ended Jun 30, 2025), down 28.5% from fiscal 2024.
Moolec Science SA (MLEC) financials
For fiscal 2025 (ended Jun 30, 2025), Moolec Science SA reported $333.61M of revenue and -$111.46M of net income.
- Revenue, FY2025
- $333.61M
- Revenue growth, YoY
- -28.5%
- Net income, FY2025
- -$111.46M
- Net margin
- -33.4%
- Free cash flow, FY2025
- -$2.02M
- EPS, diluted, FY2025
- -$17.25
- Cash
- $767.9K
- Total debt
- $1.35M
- P/S
- 0.00
- Market cap
- $1.2M
FY2023FY2025
FY2022FY2025
FY2023FY2025
MLEC revenue and earnings growth
MLEC net incomeFY2025-$111.46M
MLEC net income was -$111.46M for fiscal 2025 (ended Jun 30, 2025), compared with -$32.69M in fiscal 2024.
MLEC EPSFY2025-$17.25
MLEC diluted EPS was -$17.25 for fiscal 2025 (ended Jun 30, 2025).
MLEC free cash flowFY2025-$2.02M
MLEC free cash flow was -$2.02M for fiscal 2025 (ended Jun 30, 2025), compared with $29.62M in fiscal 2024.
Income statement
| Line item | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
|---|---|---|---|---|
| Revenue | $333.61M | $466.38M | $420.87M | - |
| Cost of revenue | $203.42M | $279.37M | $235.46M | - |
| Gross profit | $130.19M | $187.01M | $185.40M | - |
| Research and development | $15.14M | $17.42M | $15.94M | $985.2K |
| Selling, general and admin | $125.91M | $126.34M | $116.53M | $2.52M |
| Operating income | -$104.15M | $19.28M | $98.05M | -$3.65M |
| Interest expense | - | $41.1K | $160.0K | $2.1K |
| Pre-tax income | -$170.00M | -$27.96M | $50.79M | -$4.53M |
| Income tax | $6.64M | $1.10M | -$2.33M | - |
| Net income | -$111.46M | -$32.69M | $40.44M | -$4.53M |
| EPS, basic | -$17.25 | -$5.61 | $8.80 | -$0.15 |
| EPS, diluted | -$17.25 | -$5.61 | $8.80 | -$0.15 |
| Diluted shares | - | 37.9M | 34.5M | 31.0M |
Balance sheet
| Line item | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
|---|---|---|---|---|
| Cash and equivalents | $767.9K | $52.99M | $2.53M | $1.08M |
| Receivables | - | $1.01M | $1.33M | - |
| Inventory | $2.24M | $125.93M | $465.7K | - |
| Current assets | $31.19M | $438.21M | $5.33M | $1.08M |
| Goodwill | - | $112.16M | $251.4K | - |
| Total assets | $204.71M | $949.84M | $24.05M | $5.69M |
| Current liabilities | $236.05M | $427.40M | $12.60M | $4.09M |
| Long-term debt | $1.35M | $127.25M | - | - |
| Total debt | $1.35M | $127.25M | - | - |
| Total liabilities | $287.58M | $699.84M | $13.95M | $4.09M |
| Shareholders' equity | -$65.97M | $1.21M | $258.57M | $124.87M |
Cash flow
| Line item | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
|---|---|---|---|---|
| Operating cash flow | $3.64M | $39.56M | -$41.16M | -$1.89M |
| Capital expenditures | $5.65M | $9.94M | $11.49M | - |
| Free cash flow | -$2.02M | $29.62M | -$52.65M | - |
| Investing cash flow | -$35.99M | -$27.40M | -$25.59M | - |
| Financing cash flow | -$15.02M | -$1.49M | $76.22M | $2.00M |
| Stock-based compensation | $4.39M | $14.20M | $3.48M | $838.6K |
| Depreciation and amortization | - | - | $122.0K | $1.7K |
Key ratios
| Line item | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
|---|---|---|---|---|
| Revenue growth, YoY | -28.5% | 10.8% | - | - |
| Gross margin | 39.0% | 40.1% | 44.1% | - |
| Operating margin | -31.2% | 4.1% | 23.3% | - |
| Net margin | -33.4% | -7.0% | 9.6% | - |
| Free cash flow margin | -0.6% | 6.4% | -12.5% | - |
| Return on equity | - | -2695.0% | 15.6% | -3.6% |
| Return on assets | -54.4% | -3.4% | 168.1% | -79.5% |
| Current ratio | 0.13 | 1.03 | 0.42 | 0.27 |
| Debt to equity | - | 104.92 | - | - |
Source: XBRL data Moolec Science SA files with the SEC, latest filing dated Dec 29, 2025 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
MLEC peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| MLEC | $333.61M | -28.5% | -$111.46M | -33.4% | $1.2M |
| TACO | $11.6K | - | $9.36M | 80937.6% | $382.6M |
| PRE | $30.62M | +40.8% | -$46.30M | -151.2% | $270.0M |
| OXSQ | - | - | -$32.87M | - | $105.7M |
| INV | $3.75M | +154.7% | -$120.38M | -3208.4% | $12.0M |
MLEC FAQ
9 questionsWhat is MLEC revenue?
Moolec Science SA (MLEC) reported $333.61M of revenue for fiscal 2025 (ended Jun 30, 2025). That is down 28.5% from the year before.Is MLEC profitable?
No. Moolec Science SA reported a net loss of $111.46M for fiscal 2025 (ended Jun 30, 2025).How much cash and debt does MLEC have?
Moolec Science SA reported $767.9K in cash and cash equivalents and $1.35M of debt on its most recent balance sheet in SEC filings.How fast is MLEC revenue growing?
Moolec Science SA's revenue changed -28.5% in fiscal 2025, to $333.61M.What is MLEC gross margin?
Moolec Science SA's gross profit was $130.19M on $333.61M of revenue for fiscal 2025 (ended Jun 30, 2025), a gross margin of 39.0%.What is MLEC free cash flow?
Moolec Science SA generated -$2.02M of free cash flow for fiscal 2025 (ended Jun 30, 2025), which is operating cash flow of $3.64M less capital expenditures.What is MLEC earnings per share?
Diluted earnings per share were -$17.25 for fiscal 2025 (ended Jun 30, 2025), from SEC filings, restated for any stock split those filings show.When did MLEC last report financial results?
The latest statements here come from Moolec Science SA's 20-F filed on Dec 29, 2025, covering the period ended Jun 30, 2025.Where does this MLEC financial data come from?
Quantisnow builds these statements from the structured XBRL data Moolec Science SA files with the SEC. It is provided for information only and is not investment advice.